Medicines regulation, pricing and reimbursement in Brazil
Brazil is an upper-middle-income country with a high human development index (HDI) of 0.765 (2019). The Unique Health System (SUS) is a universal, decentralised system, free at point-of-care, although 27% of Brazilians have voluntary supplementary health insurance. Medicines are provided free-of-cha...
Saved in:
Main Authors: | Adriana M. IVAMA-BRUMMELL (Author), Daniella PINGRET-KIPMAN (Author), Priscila G. LOULY (Author), Rosiene R. ANDRADE (Author) |
---|---|
Format: | Book |
Published: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Medicines pricing and reimbursement: innovation, competitiveness, and access
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022) -
Pharmaceutical regulation, pricing, coverage and policy reform in the United States of America
by: Mariana P. SOCAL, et al.
Published: (2022) -
Medicines pricing and reimbursement in Canada
by: Chris BONNETT, et al.
Published: (2022)